Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Dollars as a global currency, loan, credit, and payment concept. A hand offering 100 US dollars. Minimalist art collage

Collaboration

Eli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines

The collaboration focuses on ‘molecular gates,’ a class of molecules that the startup company Gate Bioscience says can stop pathogenic proteins from leaving the cell.

July 25, 2025

1 min read

Dan Samorodnitsky

Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.

Regulatory

Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne muscular dystrophy.

July 25, 2025

2 min read

Tristan Manalac

Layoffs

Rocket Trims Headcount and Pipeline Focus Amid Clinical, Regulatory Turbulence

The strategic reprioritization comes after the company hit two major hurdles in the past year, including a clinical hold for an investigational gene therapy and an FDA rejection for its lead asset.

July 25, 2025

2 min read

Tristan Manalac

Problems and Challenges. Businessman stands on question mark

Gene therapy

Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an anonymous senior FDA official. Given Elevidys’ full approval, however, experts told BioSpace this path would set up a length legal battle between the regulator and Sarepta Therapeutics.

July 25, 2025

4 min read

Tristan Manalac

Facade of AstraZeneca's office in Shanghai, China

Autoimmune disease

AstraZeneca Claims PIII Win With Nanobody Treatment for Myasthenia Gravis

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL trial and promised to share more at an upcoming scientific meeting.

July 24, 2025

2 min read

Dan Samorodnitsky

Cairo, Egypt, October 31 2024: Novartis CO building in Egypt, Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland, manufactures the drugs

I&I

Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint

The partnership with Matchpoint Therapeutics gets Novartis global rights on all molecules for several unannounced inflammatory diseases identified through the biotech’s discovery platform.

July 24, 2025

2 min read

Dan Samorodnitsky

Illustration showing businesswoman surprised by lost connection

Layoffs

Tales of the Weird: How Some Biopharma Employees Found Out About Layoffs

Companies sometimes miss the mark when it comes to telling employees they’re out of a job. From accidental goodbyes to surprise meetings, there are many strange ways biopharma professionals have learned about layoffs.

July 24, 2025

4 min read

Angela Gabriel